TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of subjects with 4-fold rise in serum vibriocidal antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Constant Scale Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASES Scale Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DASH Scale Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS Scale Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Weight During Counseling Program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Diagnosed With COVID-19 Who Were Hospitalized
Endpoint domain: Mortality/survival
Primary endpoint: Core Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one-year disease free survival (DFS-1y)
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusion Capacity (DLco)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Detection of primary tumours and metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Functional shoulder score according to Constant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of clinical remission (CDAI <150)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete removal of common bile duct stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pre-Verbal Communication Skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Absolute Vaccine Efficacy (VE)
Endpoint domain: Mortality/survival
Primary endpoint: Solicited Local and Systemic Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Serial PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post treatment biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progression-free Survival at ≤12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free Survival at ≤36 Months
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free Survival at ≤48 Months
Endpoint domain: Mortality/survival
Primary endpoint: Response Rate (Complete, Partial Response and Stable Disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: child BMI z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Collapsibility index of the inferior vena cava (IVC-CI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Minimum diameter of the inferior vena cava (IVC-min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum diameter of the inferior vena cava (IVC-max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Human Serum Osteocalcin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nonadherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Compliance With Tarka Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Image Quality as Assessed by Ratio of Tissue Density of Main Portal Vein (MPV) to the Aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image Quality as Assessed by Ratio of Tissue Density of Spleen to the Aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image Quality as Assessed by Ratio of Tissue Density of Inferior Vena Cava (IVC) to the Aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image Quality as Assessed by Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density (BMD) and Bone mineral content (BMC) height z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported resident competency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Validation of computational biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate Specific Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of False Positive signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time rate of False Positive signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zarit Burden Interview Scale
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Family Needs Survey (FNS)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Conduit artery endothelial-dependent function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in OCD symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child and Adolescent Scale of Participation (CASP)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Caregiver Priorities & Child Health Index of Life with Disabilities (CPCHILD)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants with grade 4-5 late adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Progression-free Patients by Month 6
Endpoint domain: Mortality/survival
Primary endpoint: heart failure signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PET amyloid Standard Uptake Value ratio (SUVr) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Transcranial Doppler (TCD) dynamic autoregulatory dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of patients treated with intravenous thrombolysis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Contrast induced nephropathy incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference of Δ SUV between 18F-FDG PET 1 and 18F-FDG PET 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in numeric rating scale (NRS) of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale (VAS) Pain Score at Rest and Exertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' Satisfaction Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Complete Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Cryptosporidiosis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of HF-related Hospital Days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in the Brief Pain Inventory (Short Form) Score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Percent Change of 17-OHP Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Frequencies of genotypes and haplotypes of genes involved in drug responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities of cytochrome P450 enzymes and P-gp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in corrected distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic properties of CAM French Version
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bacterial bioburden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Program completion
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Hepatic Lipogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor Shrinkage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Grief Intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of participants with complications
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported patient global assessment (PGA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NYHA functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Completion rate of exercise rehabilitation program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of peak O2 uptake (VO2peak) during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: O2 sats
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep category
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Feeding (sucking and absorption) category
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neonatal Abstinence Scoring (NAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysphagia screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior Chamber Cell Grade of 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional dimension of dyspnea
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lymphocyte infiltration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of biogenic amine symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Level (Cmax) Following a Single Dose of Bimatoprost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Level (Cmax) Following Multiple Doses of Bimatoprost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Visual Analog Scale (VAS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cause specific survival
Endpoint domain: Mortality/survival
Primary endpoint: Area under the curve (AUC) of rifabutine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston naming test evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Western Aphasia Battery (WAB) Speech fluency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Western Aphasia Battery (WAB) Repetition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Western Aphasia Battery (WAB) Word recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Syntax comprehension part of Bilingual aphasia test (Standard Modern Chinese Version)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intraoperative Visual Field Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intraoperative maximum systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the mean number of night-time voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in mean patient reported nocturia bother score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 3-Day Voiding Diary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Distress scale(SDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: King's Health Questionnaire (KHQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline in Montgomery-Åsberg Depression Rating Scale (Self-report version)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Timed up and go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoride concentration in dental plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative changes in ROTEM MCF EXTEM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in sperm DNA damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in depigmentation of vitiligo lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in melanin content of vitiligo lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sensitivity and specificity of neuromonitoring technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pump failures
Endpoint domain: Adverse events/effects
Primary endpoint: Red blood cell concentrations of Glutathione
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum catecholamine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean number of urgency episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peritoneal carcinomatosis staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Level of depression one month after screening
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of respiratory symptoms defined by CAT≥10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Functional exercise incapacity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Respiratory exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of disease progression
Endpoint domain: Adverse events/effects
Primary endpoint: Quantra Clot Time test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantra Clot Stiffness test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantra Fibrinogen Contribution to Clot Stiffness test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quantra Platelet Contribution to Clot Stiffness test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decisional balance level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Readiness to change level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: proportion of volunteers with severe local and systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of volunteers with other SAEs related to study vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of volunteers with HIV-1 specific T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functional motor recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Shoulder function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Any Grade 2 or Higher Event in the Injection Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Vital Sign Assessment for Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in the Injection Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Vital Sign Assessment for Heart Rate (HR) in the Injection Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aphasia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination Rate of Barrett's Esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hematologic and cytogenetic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Stable mean DNA-TGN level > 500 fmol/microgram DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of pain during statin treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Gait Spatiotemporal and Kinematic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year local recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Clinically significant changes in laboratory safety tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in CNC Word Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lateral Orbital Frontal Cortex Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nucleus Accumbens Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Changes in Lean Body Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of Petroleum Jelly in Treating Nonscalp Seborrheic Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Spread of coloring solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Stricture Formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute (Serious System and Procedure Related Adverse Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term (Study Related Adverse Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in number of blood products utilized
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Side effects of chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: AUC (0-infinity) or AUC (0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax and T1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral embolism incidence
Endpoint domain: Mortality/survival
Primary endpoint: Mean percent change in inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent change in non-inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: γδ-T cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gleason Grade Group 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Seroconverted Subjects for Anti-Haemagglutination Inhibition (HI) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms (Excluding Fever)
Endpoint domain: Adverse events/effects
Primary endpoint: Hormone changes during hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants Achieving Confirmed Response (CR), VGPR, or PR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of 25-hydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma concentrations of estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Identify biomarkers of disease-related transitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Evaluate the use of sensor technologies for the collection of continuous, accurate health information
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure the phenotypic diversity observed among a participant population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of current diagnosed hypertensive patients with BP <140/90 (or BP<130/80 for patients with diabetes) at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes